<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505944</url>
  </required_header>
  <id_info>
    <org_study_id>NLG-MCL7</org_study_id>
    <secondary_id>2017-001060-38</secondary_id>
    <nct_id>NCT03505944</nct_id>
  </id_info>
  <brief_title>Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma</brief_title>
  <acronym>VALERIA</acronym>
  <official_title>Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Lymphoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Lymphoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of&#xD;
      rituximab-lenalidomide in patients with relapsed/refractory MCL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>6 months</time_frame>
    <description>The primary objective is to assess the overall response rate (ORR) at 6 months with lenalidomide-venetoclax and rituximab, in patients with relapsed or refractory mantle cell lymphoma, by use of an MRD driven strategy. ORR includes complete (CR) and partial remissions (PR).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Relapsed Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax+lenalidomide+rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>venetoclax + lenalidomide + rituximab</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Histologically confirmed (according to the WHO 2016 classification) mantle cell&#xD;
             lymphoma stage I-IV&#xD;
&#xD;
               -  Who have received at least 1 prior rituximab-containing chemotherapy regimen,&#xD;
                  with documented relapse or disease progression following the last anti-MCL&#xD;
                  treatment OR&#xD;
&#xD;
               -  Are not considered to be candidates for chemotherapy due to frailty or&#xD;
                  comorbidity&#xD;
&#xD;
          -  At least 1 measurable site of disease (&gt;1.5 cm long axis)&#xD;
&#xD;
          -  WHO performance status 0 - 3&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Female subjects of childbearing potential must (see page 52 for definition of not&#xD;
             fertile):&#xD;
&#xD;
               -  Understand that the study medication is expected to be teratogenic&#xD;
&#xD;
               -  Agree to use, and be able to comply with, highly effective contraception without&#xD;
                  interruption, 4 weeks before starting study drug, throughout study drug therapy&#xD;
                  (including dose interruptions) and for 4 weeks after the end of study drug&#xD;
                  therapy, even if she has amenorrhoea.&#xD;
&#xD;
               -  All fertile women must agree to perform monthly pregnancy tests while on study&#xD;
                  medication and until 4 weeks after completion of study drug. Tests must have a&#xD;
                  minimum sensitivity of 25 mIE/ml and be medically witnessed&#xD;
&#xD;
               -  Highly effective contraception include:&#xD;
&#xD;
        Implant* Levonorgestrel-releasing intrauterine system (IUS)* Medroxyprogesterone acetate&#xD;
        depot Tubal sterilisation Sexual intercourse with a vasectomised male partner only;&#xD;
        vasectomy must be confirmed by two negative semen analyses Ovulation inhibitory&#xD;
        progesterone-only pills (i.e., desogestrel) NB! Patients using a hormonal method, must also&#xD;
        use a second barrier method. Sexual abstinence (if refraining from heterosexual intercourse&#xD;
        during the entire period of risk associated with the study treatments. The reliability of&#xD;
        sexual abstinence needs to be evaluated in relation to the preferred and usual lifestyle of&#xD;
        the subject).&#xD;
&#xD;
          -  Male subjects must&#xD;
&#xD;
               -  Agree to use condoms throughout study drug therapy, during any dose interruption&#xD;
                  and for one week after cessation of study therapy if their partner is of&#xD;
                  childbearing potential and has no contraception.&#xD;
&#xD;
               -  Agree not to donate semen during study drug therapy and for one week after end of&#xD;
                  study drug therapy.&#xD;
&#xD;
          -  All subjects must&#xD;
&#xD;
               -  Agree to abstain from donating blood while taking study drug therapy and for one&#xD;
                  week following discontinuation of study drug therapy.&#xD;
&#xD;
               -  Agree not to share study medication with another person and to return all unused&#xD;
                  study drug to the investigator&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Chemotherapy or radiotherapy within 3 weeks&#xD;
&#xD;
          -  Therapeutic antibodies or BTK inhibitors within 4 weeks&#xD;
&#xD;
          -  Radioimmunotherapy within 10 weeks&#xD;
&#xD;
          -  Major surgery within 4 weeks of inclusion in this trial.&#xD;
&#xD;
          -  Previous treatment with venetoclax&#xD;
&#xD;
          -  Impaired liver function: AST and ALT &gt;3.0 × the upper normal limit (ULN) of&#xD;
             institution's normal range; Bilirubin &gt; 1.5 × ULN. Subjects with Gilbert's Syndrome&#xD;
             may have a bilirubin &gt; 1.5 × ULN, per discussion between the investigator and medical&#xD;
             monitor. Elevated Bilirubin due to haemolytic anemia or caused by lymphoma, is not an&#xD;
             exclusion criterion.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt;1.0x 109, unless caused by bone marrow infiltration&#xD;
             by lymphoma.&#xD;
&#xD;
          -  Platelet count &lt;60 x 109, unless caused by bone marrow infiltration by lymphoma.&#xD;
&#xD;
          -  Creatinine clearance below 50 ml/min (Cockcroft-Gault)&#xD;
&#xD;
          -  Known CNS lymphoma.&#xD;
&#xD;
          -  Heart failure in NYHA stage IV or other serious CVD&#xD;
&#xD;
          -  Pulmonary failure (ex chronic disease with hypoxemia)&#xD;
&#xD;
          -  Active serious infections such as hepatitis B or C and HIV&#xD;
&#xD;
          -  Conditions with serious immunocompromised state&#xD;
&#xD;
          -  Breastfeeding women must be excluded or stop breastfeeding&#xD;
&#xD;
          -  Other active malignancy.&#xD;
&#xD;
          -  Psychiatric illness or condition which could interfere with the subjects' ability to&#xD;
             understand the requirements of the study.&#xD;
&#xD;
          -  Requirement of corticosteroid therapy at a dose &gt;10 mg prednisolone/day.&#xD;
&#xD;
          -  Hypersensitivity to venetoclax, lenalidomide or rituximab, or HACA against rituximab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mats Jerkeman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hematology Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Hematology L-4241 Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology X Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hæmatologisk Afdeling Zeeland University Hospital, Roskilde</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology Helsinki University Hospital Comprehensive Cancer Center</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olav Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine Sunderbyn Hospital</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology Norrland University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsla Academic Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

